Back to News
Market Impact: 0.25
CAPR Class Alert: Capricor Therapeutics Securities Fraud Class Action to Recover Losses is Pending – Investors Notified to Contact BFA Law before September 28 Court Deadline
Source: globenewswire.com
Legal & LitigationHealthcare & Biotech
A securities-fraud class action seeking to recover investor losses is pending against Capricor Therapeutics, with investors instructed to contact BFA Law before the September 28 lead-plaintiff deadline. The notice signals material litigation risk for the biotech company, though no alleged damages, financial impact, or case-specific allegations were provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly negative
Sentiment Score
-0.55
Ticker Sentiment
CAPR-0.90
More News
- J&J's potential 'game-changer' drug — plus, what Microsoft's mass buyouts mean
- ‘Imposed significant financial harm’: 20 states join the FTC in suing Dollar General for ‘deceptive pricing practices’ despite ‘corporate knowledge’
- The excitement around Moderna’s cancer vaccine is cooling. Here’s why.
- Anthropic’s dual-class share structure borrows ideas from Mark Zuckerberg, Elon Musk—and the New York Times
- Cramer: I asked some tech insiders what to buy. They surprisingly said this drug stock
- Genmab shares jump 13% on colorectal cancer drug trial results